{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=50", "query": { "condition": "Relapsed/Refractory", "page": 50 }, "page_size": 10 }, "pagination": { "page": 50, "page_size": 10, "total_count": 3666, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=51&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=49&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T09:37:34.543Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01980628", "title": "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Marginal Zone Lymphoma", "B-cell Lymphoma" ], "interventions": [ { "name": "ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2013-12", "completion_date": "2017-10-02", "has_results": true, "last_update_posted_date": "2019-10-16", "last_synced_at": "2026-11-14T09:37:34.543Z", "location_count": 13, "location_summary": "Tucson, Arizona • Duarte, California • Santa Monica, California + 8 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01980628" }, { "nct_id": "NCT06026319", "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-hodgkin Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Diffuse Large B Cell Lymphoma", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "High-grade B-cell Lymphoma", "Grade 3b Follicular Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "CD79b-19 CAR T cells", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marcela V. Maus, M.D.,Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-10-26", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-14T09:37:34.543Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06026319" }, { "nct_id": "NCT00014664", "title": "Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "apolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "PDL BioPharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-11-14T09:37:34.543Z", "location_count": 1, "location_summary": "Freemont, California", "locations": [ { "city": "Freemont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014664" }, { "nct_id": "NCT00698009", "title": "Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Natural Killer Cell Infusion", "type": "BIOLOGICAL" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1, "start_date": "2008-06", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-11-14T09:37:34.543Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00698009" }, { "nct_id": "NCT05896228", "title": "Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma", "Relapsed Multiple Myeloma" ], "interventions": [ { "name": "Iberdomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Benjamin T Diamond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2024-02-20", "completion_date": "2031-03-01", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-11-14T09:37:34.543Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05896228" }, { "nct_id": "NCT00671112", "title": "Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "714leukemia", "Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brian Hill, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-11-14T09:37:34.543Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671112" }, { "nct_id": "NCT04900519", "title": "Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Relapsed Solid Neoplasm", "Refractory Tumor" ], "interventions": [ { "name": "STI-6643", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sorrento Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2021-11-24", "completion_date": "2025-03", "has_results": false, "last_update_posted_date": "2023-01-17", "last_synced_at": "2026-11-14T09:37:34.543Z", "location_count": 5, "location_summary": "San Diego, California • Sioux Falls, South Dakota • Austin, Texas + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Sioux Falls", "state": "South Dakota" }, { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900519" }, { "nct_id": "NCT00054665", "title": "PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Lymphoma" ], "interventions": [ { "name": "PS-341", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2003-02", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2012-09-11", "last_synced_at": "2026-11-14T09:37:34.543Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Buffalo, New York", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054665" }, { "nct_id": "NCT00309907", "title": "Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Disseminated Neuroblastoma", "Juvenile Myelomonocytic Leukemia", "Previously Treated Childhood Rhabdomyosarcoma", "Previously Treated Myelodysplastic Syndromes", "Pulmonary Complications", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "etanercept", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 39, "start_date": "2006-04", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2017-09-29", "last_synced_at": "2026-11-14T09:37:34.543Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Arcadia", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309907" }, { "nct_id": "NCT01212952", "title": "Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "pomalidomide", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "gene expression analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2011-09", "completion_date": "2018-03-22", "has_results": true, "last_update_posted_date": "2020-04-17", "last_synced_at": "2026-11-14T09:37:34.543Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01212952" } ] }